By Indu Tyagi Ketan, 19 October, 2022
DaxibotulinumtoxinA (Daxxify), Revance's long-awaited Botox rival, has officially received FDA approval, as the company is now gearing up to establish its brand. Daxxify is an intravenous neuromodulator similar to Botox; its novel peptide exchange technology temporarily eases the moderate to severe glabellar (frown) lines.
The trials revealed that a single injection had a significant anti-wrinkle impact on durational effects were proven in phase 3 trials with 4,200 treatments and 2,700 patients. The chief differentiator for Daxxify is its endurance; it can last six months and has even proven effective for up to nine months in some individuals, vis-a-vis Botox injections that last only for three months.
Daxxify was initially scheduled to receive FDA approval in November 2020, but the epidemic slowed inspection. After visiting Revance's production facility, inspectors discovered quality control and record-keeping issues. The FDA then issued Revance a detailed response letter in October of last year. Soon after, the FDA approved the changes in July after Revance resolved all five problems mentioned in the Complete Response Letter.
Indu Tyagi Ketan
Chief Strategy Officer
The market for passenger cars with autonomous driving features will be growing daily in 2023. In the era of autonomous driving, passengers can sit back relaxing, and vehicles can handle driving with the automation facility.
In San Francisco, the…
The United States has decided to cut the prices of certain medical drugs in 2023. It is due to the Inflation Reduction Act of 2022, recently signed by the government of the United States in 2022. The report includes specific provisions to lower the…
The African region is emerging as a developing nation with growth in its gross domestic product (GDP). Various reasons contribute to Africa as an emerging nation in 2023. Seychelles is the most developed nation in Africa, with a gross domestic…
Robots and automation have set up their base in the technologically evolving market, thus impacting the job market. The market is expected to grow in robots and automation soon. A new question has arisen in the United States on whether to implement a…